Clinical trial
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
NCT05710185 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Deucravacitinib for the Treatment of Palmoplantar Pustulosis
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- July 1, 2023
- Completion date
- January 31, 2025
- Enrollment
- 3 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
palmoplantar pustulosis